$TPST
Tempest Therapeutics, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023009237 Filed on March 22, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.903M $3.140M $12.11M
YoY Change -4.88% 19.71% 23.35%
% of Gross Profit
Research & Development $4.678M $5.794M $22.53M
YoY Change -8.44% 22.88% 31.23%
% of Gross Profit
Depreciation & Amortization $125.0K $217.0K $638.0K
YoY Change 15.74% 112.75% 70.59%
% of Gross Profit
Operating Expenses $4.678M $8.934M $22.53M
YoY Change -8.44% 21.75% 31.23%
Operating Profit -$7.581M -$34.64M
YoY Change -7.11% 28.36%
Interest Expense $344.0K -$432.0K $1.618M
YoY Change 3.3% 27.81% 26.21%
% of Operating Profit
Other Income/Expense, Net -$55.00K $263.0K -$1.069M
YoY Change -83.33% -355.34% -18.77%
Pretax Income -$7.636M -$9.103M -$35.71M
YoY Change -10.07% 17.02% 26.17%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.636M -$9.103M -$35.71M
YoY Change -10.07% -67.84% 26.17%
Net Earnings / Revenue
Basic Earnings Per Share -$0.55 -$3.09
Diluted Earnings Per Share -$0.55 -$0.66 -$3.09
COMMON SHARES
Basic Shares Outstanding 10.56M 10.52M shares 11.55M
Diluted Shares Outstanding 13.76M 11.55M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.93M $31.23M $31.23M
YoY Change -49.9% -39.74% -39.74%
Cash & Equivalents $22.90M $31.23M $31.23M
Short-Term Investments
Other Short-Term Assets $419.0K $263.0K $1.720M
YoY Change -39.36% -52.44% -89.96%
Inventory
Prepaid Expenses $594.0K $703.0K
Receivables
Other Receivables
Total Short-Term Assets $24.67M $32.95M $32.95M
YoY Change -60.66% -52.22% -52.22%
LONG-TERM ASSETS
Property, Plant & Equipment $1.008M $1.060M $12.71M
YoY Change -1.56% -4.76% 205.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $429.0K $429.0K $429.0K
YoY Change -10.63% 286.49% 286.49%
Total Long-Term Assets $12.66M $13.14M $13.14M
YoY Change 198.28% 207.35% 207.35%
TOTAL ASSETS
Total Short-Term Assets $24.67M $32.95M $32.95M
Total Long-Term Assets $12.66M $13.14M $13.14M
Total Assets $37.33M $46.09M $46.09M
YoY Change -44.25% -37.07% -37.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.157M $1.108M $1.108M
YoY Change 69.15% 11.81% 11.81%
Accrued Expenses $2.538M $2.961M $5.719M
YoY Change -21.52% 86.34% 41.73%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.481M
YoY Change
Total Short-Term Liabilities $7.511M $7.277M $7.277M
YoY Change -63.92% -63.66% -63.66%
LONG-TERM LIABILITIES
Long-Term Debt $8.935M $10.37M $10.37M
YoY Change -40.96% -31.18% -31.18%
Other Long-Term Liabilities $9.918M $10.33M $10.33M
YoY Change 501.82% 409.87% 409.87%
Total Long-Term Liabilities $8.935M $10.37M $20.70M
YoY Change -40.96% -31.18% 21.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.511M $7.277M $7.277M
Total Long-Term Liabilities $8.935M $10.37M $20.70M
Total Liabilities $26.36M $27.98M $27.98M
YoY Change -29.88% -24.63% -24.63%
SHAREHOLDERS EQUITY
Retained Earnings -$143.4M -$135.8M
YoY Change 32.11% 35.69%
Common Stock $11.00K $11.00K
YoY Change 57.14% 57.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.97M $18.11M $18.11M
YoY Change
Total Liabilities & Shareholders Equity $37.33M $46.09M $46.09M
YoY Change -44.25% -37.07% -37.07%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$7.636M -$9.103M -$35.71M
YoY Change -10.07% -67.84% 26.17%
Depreciation, Depletion And Amortization $125.0K $217.0K $638.0K
YoY Change 15.74% 112.75% 70.59%
Cash From Operating Activities -$8.303M -$6.479M -$31.07M
YoY Change 16.83% -18.86% 19.71%
INVESTING ACTIVITIES
Capital Expenditures $46.00K $356.0K $562.0K
YoY Change 1433.33% -1418.52% 316.3%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$46.00K -$356.0K -$562.0K
YoY Change 1433.33% 1218.52% 479.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $8.861M
YoY Change -73.49%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 44.00K -4.726M 11.40M
YoY Change -96.86% 52411.11% -80.69%
NET CHANGE
Cash From Operating Activities -8.303M -6.479M -31.07M
Cash From Investing Activities -46.00K -356.0K -562.0K
Cash From Financing Activities 44.00K -4.726M 11.40M
Net Change In Cash -8.305M -11.56M -20.23M
YoY Change 45.52% 44.13% -161.29%
FREE CASH FLOW
Cash From Operating Activities -$8.303M -$6.479M -$31.07M
Capital Expenditures $46.00K $356.0K $562.0K
Free Cash Flow -$8.349M -$6.835M -$31.63M
YoY Change 17.43% -14.11% 21.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001544227
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-35890
CY2022 dei Entity Registrant Name
EntityRegistrantName
Tempest Therapeutics, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-1472564
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
2000 Sierra Point Parkway
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Brisbane
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94005
CY2022 dei City Area Code
CityAreaCode
(415)
CY2022 dei Local Phone Number
LocalPhoneNumber
798-8589
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2022 dei Trading Symbol
TradingSymbol
TPST
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
22200000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10561700
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
Chicago, Illinois
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31230000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51829000
CY2022Q4 us-gaap Insurance Settlements Receivable
InsuranceSettlementsReceivable
450000
CY2021Q4 us-gaap Insurance Settlements Receivable
InsuranceSettlementsReceivable
15000000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1270000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2134000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
32950000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
68963000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1060000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1113000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11650000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3051000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
429000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
111000
CY2022Q4 us-gaap Assets
Assets
46089000
CY2021Q4 us-gaap Assets
Assets
73238000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1108000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
991000
CY2022Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
450000
CY2021Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
15000000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2961000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1589000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1413000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1442000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1248000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
912000
CY2022Q4 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
97000
CY2021Q4 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
92000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7277000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20026000
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
454000
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
756000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10371000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15069000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10330000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2026000
CY2022Q4 us-gaap Liabilities
Liabilities
27978000
CY2021Q4 us-gaap Liabilities
Liabilities
37121000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10518539
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10518539
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6910324
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6910324
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
153872000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
136173000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-135772000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-100063000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
18111000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36117000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46089000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
73238000
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
22527000
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
17166000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12113000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9820000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-34640000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-26986000
CY2022 us-gaap Interest Expense
InterestExpense
1618000
CY2021 us-gaap Interest Expense
InterestExpense
1282000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
549000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-34000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1069000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1316000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Profit Loss
ProfitLoss
-35709000
CY2021 us-gaap Profit Loss
ProfitLoss
-28302000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.09
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.09
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.47
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.47
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11548907
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11548907
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3790303
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3790303
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-68793000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
139000
CY2021 tpst Vesting Of Early Exercised Stock Options And Restricted Stock
VestingOfEarlyExercisedStockOptionsAndRestrictedStock
133000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
86707000
CY2021 tpst Stock Issuance Costs
StockIssuanceCosts
446000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
33474000
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1105000
CY2021 tpst Adjustments To Additional Paid In Capital Reverse Recapitalization Transaction Costs
AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts
6420000
CY2021 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
18001000
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
73000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-28302000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
36117000
CY2022 tpst Stock Issuance Costs
StockIssuanceCosts
489000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8861000
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1561000
CY2022 tpst Warrant Issuance Costs
WarrantIssuanceCosts
283000
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7281000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-35709000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
18111000
CY2022 us-gaap Profit Loss
ProfitLoss
-35709000
CY2021 us-gaap Profit Loss
ProfitLoss
-28302000
CY2022 us-gaap Depreciation
Depreciation
638000
CY2021 us-gaap Depreciation
Depreciation
374000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1561000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1105000
CY2022 tpst Noncash Lease Expense
NoncashLeaseExpense
1176000
CY2021 tpst Noncash Lease Expense
NoncashLeaseExpense
896000
CY2022 tpst Noncash Interest And Other Expense Net
NoncashInterestAndOtherExpenseNet
394000
CY2021 tpst Noncash Interest And Other Expense Net
NoncashInterestAndOtherExpenseNet
583000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-915000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
179000
CY2022 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1000
CY2021 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-209000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1709000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
723000
CY2022 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-256000
CY2021 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
92000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1501000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1040000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31072000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25957000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
562000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
135000
CY2021 us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
38000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-562000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-97000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8861000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
33425000
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
7281000
CY2021 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
CY2022 us-gaap Repayments Of Debt
RepaymentsOfDebt
4739000
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
15000000
CY2021 us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
95000
CY2021 tpst Proceeds From Cash Acquired In Connection With Reverse Recapitalization
ProceedsFromCashAcquiredInConnectionWithReverseRecapitalization
17045000
CY2021 tpst Payment Of Reverse Recapitalization Transaction Costs
PaymentOfReverseRecapitalizationTransactionCosts
-6420000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
108000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11403000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
59063000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-20231000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
33009000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51829000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18820000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31598000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51829000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1539000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
953000
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
18000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10660000
CY2022 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
884000
CY2022 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
93000
CY2021 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
78000
CY2021 tpst Vesting Of Early Exercise Stock Options
VestingOfEarlyExerciseStockOptions
136000
CY2021 us-gaap Stock Issued1
StockIssued1
49000
CY2022 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
30000000.0
CY2021Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-15
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5365899
CY2021Q2 tpst Business Combination Exchange Ratio
BusinessCombinationExchangeRatio
0.0322
CY2021Q2 tpst Stockholders Equity Note Stock Split Exchange Ratio
StockholdersEquityNoteStockSplitExchangeRatio
0.0322
CY2022 tpst Stockholders Equity Note Stock Split Exchange Ratio
StockholdersEquityNoteStockSplitExchangeRatio
0.0322
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31200000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, right-of-use assets, lease obligations, stock-based compensation and income taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.</span></p>
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—Financial instruments, which potentially subject the Company to concentration of risk, consist principally of cash and money market fund. All of the Company’s cash and money market fund are deposited in accounts with a major financial institution in excess of federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents to the extent recorded in the balance sheets. While the Company has not experienced any losses in such accounts, the recent failure of Silicon Valley Bank (SVB), at which the Company held cash and cash equivalents in multiple accounts, exposed the Company to significant credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors. The Company had subsequently transferred its accounts to one or more alternate depository institutions. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span></p>
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
703000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
949000
CY2022Q4 tpst Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
304000
CY2021Q4 tpst Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
632000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
263000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
553000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1270000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2134000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2421000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1937000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1361000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
824000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1060000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1113000
CY2022 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.10
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2022 us-gaap Depreciation
Depreciation
638000
CY2021 us-gaap Depreciation
Depreciation
374000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
756000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
748000
CY2022Q4 tpst Accrued Clinical Trial Liability
AccruedClinicalTrialLiability
2205000
CY2021Q4 tpst Accrued Clinical Trial Liability
AccruedClinicalTrialLiability
841000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2961000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1589000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2613000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2100000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1861000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1926000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1994000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
6410000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
16904000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5161000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11743000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1413000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10330000
CY2022Q1 tpst Litigation Expense Amount Covered By Insurance
LitigationExpenseAmountCoveredByInsurance
15000000
CY2022Q4 tpst Litigation Settlement
LitigationSettlement
0
CY2021Q4 tpst Litigation Settlement
LitigationSettlement
15000000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
452165
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.35
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
10400000
CY2021Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
135936731
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
135936731
CY2021Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
114686731
CY2021Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
114686731
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
114686731
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
114686731
CY2021Q2 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
100187000
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
100187000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
99414000
CY2020 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
99414000
CY2021Q2 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
86706000
CY2020Q4 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
86706000
CY2021Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5365899
CY2021Q2 tpst Stockholders Equity Note Stock Split Exchange Ratio
StockholdersEquityNoteStockSplitExchangeRatio
0.0322
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10518539
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10518539
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6910324
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6910324
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021 tpst Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Reverse Recapitalization In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod
177591
CY2021 tpst Share Based Compensation Arrangements By Share Based Payment Award Optionsassumed In Reverse Recapitalization In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice
179.79
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
307529
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.78
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
33127
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.20
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
113521
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
115.72
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
790637
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.82
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
909527
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.34
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
147123
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
128.79
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1553041
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.66
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1553041
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M25D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.66
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1553041
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y6M25D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
6.66
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
473471
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M14D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.65
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1007000
CY2022Q4 tpst Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
3476000
CY2021Q4 tpst Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
903000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
104000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
146933000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3476000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1561000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1105000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7497000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5906000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2733000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-3887000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
8581000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
9154000
CY2022 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
1173000
CY2021 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
767000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2606000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1366000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
216000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
40000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
131346000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
125111000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
18122000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
16670000
CY2022Q4 tpst Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Amortization
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization
916000
CY2021Q4 tpst Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Amortization
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization
1094000
CY2022Q4 tpst Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
3504000
CY2021Q4 tpst Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
1027000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
576000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3784000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
378000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
254000
CY2022Q4 tpst Deferred Tax Assets Capital Research And Development
DeferredTaxAssetsCapitalResearchAndDevelopment
4138000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
10000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
158990000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
147940000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
155514000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3476000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1007000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022 tpst Deferred Tax Assets And Valuation Allowance Deferred Tax Asset Period Increase Decrease Amount
DeferredTaxAssetsAndValuationAllowanceDeferredTaxAssetPeriodIncreaseDecreaseAmount
8600000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
466000000.0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
434400000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
452400000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
394100000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4293000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1280000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
2767000
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
357000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
246000
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2022 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2021 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4650000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4293000
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
126000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-35709000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-28302000
CY2022 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
11548907
CY2021 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
3799392
CY2022 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2021 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
9089
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11548907
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11548907
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3790303
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3790303
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.09
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.09
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.47
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.47
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1559077
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
796673

Files In Submission

Name View Source Status
0000950170-23-009237-index-headers.html Edgar Link pending
0000950170-23-009237-index.html Edgar Link pending
0000950170-23-009237.txt Edgar Link pending
0000950170-23-009237-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img41036845_0.jpg Edgar Link pending
img41036845_1.jpg Edgar Link pending
img41036845_2.jpg Edgar Link pending
img41036845_3.jpg Edgar Link pending
img41036845_4.jpg Edgar Link pending
img41036845_5.jpg Edgar Link pending
img41036845_6.jpg Edgar Link pending
img41036845_7.jpg Edgar Link pending
img41036845_8.jpg Edgar Link pending
img41036845_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tpst-20221231.htm Edgar Link pending
tpst-20221231.xsd Edgar Link pending
tpst-ex10_24.htm Edgar Link pending
tpst-ex23_1.htm Edgar Link pending
tpst-ex31_1.htm Edgar Link pending
tpst-ex31_2.htm Edgar Link pending
tpst-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
tpst-20221231_lab.xml Edgar Link unprocessable
tpst-20221231_pre.xml Edgar Link unprocessable
tpst-20221231_htm.xml Edgar Link completed
tpst-20221231_def.xml Edgar Link unprocessable
tpst-20221231_cal.xml Edgar Link unprocessable